Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | ILK | Q13418 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6875429 | 0.91 | TDP1 (0.56) | ALDH1A1CYP3A4TDP1HPGDTSHR | |
| SCHEMBL5206462 | 0.89 | ALDH1A1 (0.56) | ALDH1A1CYP3A4TDP1HPGDTSHR | |
| SCHEMBL21902256 | 0.88 | CYP3A4 (0.53) | ALDH1A1CYP3A4TDP1HPGDTSHR | |
| SCHEMBL3037816 | 0.88 | CYP3A4 (0.53) | ALDH1A1CYP3A4TDP1HPGDTSHR | |
| SCHEMBL3042793 | 0.88 | CYP3A4 (0.53) | ALDH1A1CYP3A4TDP1HPGDTSHR | |
| SCHEMBL687610 | 0.88 | SMN1; SMN2 (0.66) | ALDH1A1CYP3A4TDP1HPGDTSHR | |
| SCHEMBL30189863 | 0.87 | CYP3A4 (0.56) | ALDH1A1CYP3A4TDP1HPGDTSHR | |
| SCHEMBL18416893 | 0.87 | CYP3A4 (0.56) | ALDH1A1CYP3A4TDP1HPGDTSHR | |
| Bromide SCHEMBL21839448 | 0.86 | CYP3A4 (0.51) | ALDH1A1CYP3A4TDP1HPGDTSHR | |
| SCHEMBL3046443 | 0.86 | CYP3A4 (0.51) | ALDH1A1CYP3A4TDP1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199561-A1 | INHIBITORS OF DYRK AND PIM | COLD SPRING HARBOR LABORATORY (US) | 2024-06-20 | — | — | US | disclosed |
| US-20170029655-A1 | POLYMERIZABLE COMPOUND, COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY DEVICE, AND ORGANIC EL DEVICE | DIC CORPORATION (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| EP-1343561-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-6965033-B2 | Bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | JIANG TAO (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1343561-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002047762-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
| US-4060544-A | COUPLERS | GAF CORPORATION (US) | 1977-11-29 | — | — | US | disclosed |
| US-4039524-A | Keto-amido containing phenylazo benzothiazole dyestuffs | GAF CORPORATION (US) | 1977-08-02 | — | — | US | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
| US-3931145-A | POLYESTER | GAF CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | ALDH1A1 852/4885CYP3A4 1052/4885TDP1 806/4885 |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, PFKFB2 | ALDH1A1 1609/4885CYP3A4 1082/4885TDP1 1345/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | ALDH1A1 1609/4885CYP3A4 1082/4885TDP1 1345/4885 |
| US-20240199561-A1 | INHIBITORS OF DYRK AND PIM | PIM3, PIM2, PIM1 | ALDH1A1 3740/4885CYP3A4 240/4885TDP1 1551/4885 |
| US-20170029655-A1 | POLYMERIZABLE COMPOUND, COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY DEVICE, AND ORGANIC EL DEVICE | OCIAD1, OCIAD2, ELOC | ALDH1A1 3129/4885CYP3A4 3233/4885TDP1 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.